453 related articles for article (PubMed ID: 16804518)
21. Suppression of STAT3 Signaling by Δ9-Tetrahydrocannabinol (THC) Induces Trophoblast Dysfunction.
Chang X; Bian Y; He Q; Yao J; Zhu J; Wu J; Wang K; Duan T
Cell Physiol Biochem; 2017; 42(2):537-550. PubMed ID: 28578322
[TBL] [Abstract][Full Text] [Related]
22. Characterization of cannabinoid agonists and apparent pA2 analysis of cannabinoid antagonists in rhesus monkeys discriminating Delta9-tetrahydrocannabinol.
McMahon LR
J Pharmacol Exp Ther; 2006 Dec; 319(3):1211-8. PubMed ID: 16943255
[TBL] [Abstract][Full Text] [Related]
23. Cannabinoid receptor expression in non-small cell lung cancer. Effectiveness of tetrahydrocannabinol and cannabidiol inhibiting cell proliferation and epithelial-mesenchymal transition in vitro.
Milian L; Mata M; Alcacer J; Oliver M; Sancho-Tello M; Martín de Llano JJ; Camps C; Galbis J; Carretero J; Carda C
PLoS One; 2020; 15(2):e0228909. PubMed ID: 32049991
[TBL] [Abstract][Full Text] [Related]
24. [Temozolomide in patients with a glioblastoma multiforme: new developments].
Bromberg JE; Postma TJ
Ned Tijdschr Geneeskd; 2005 Jun; 149(25):1376-8. PubMed ID: 15997689
[TBL] [Abstract][Full Text] [Related]
25. Cannabinoid receptor binding and mRNA levels in several brain regions of adult male and female rats perinatally exposed to delta9-tetrahydrocannabinol.
García-Gil L; Romero J; Ramos JA; Fernández-Ruiz JJ
Drug Alcohol Depend; 1999 Jun; 55(1-2):127-36. PubMed ID: 10402157
[TBL] [Abstract][Full Text] [Related]
26. Delta-9-tetrahydrocannabinol differentially suppresses emesis versus enhanced locomotor activity produced by chemically diverse dopamine D2/D3 receptor agonists in the least shrew (Cryptotis parva).
Darmani NA; Crim JL
Pharmacol Biochem Behav; 2005 Jan; 80(1):35-44. PubMed ID: 15652378
[TBL] [Abstract][Full Text] [Related]
27. Clinical trial of external beam-radiotherapy combined with daily administration of low-dose cisplatin for supratentorial glioblastoma multiforme--a pilot study.
Shinoda J; Sakai N; Hara A; Ueda T; Sakai H; Nakatani K
J Neurooncol; 1997 Oct; 35(1):73-80. PubMed ID: 9266443
[TBL] [Abstract][Full Text] [Related]
28. Antitumor effects of ajulemic acid (CT3), a synthetic non-psychoactive cannabinoid.
Recht LD; Salmonsen R; Rosetti R; Jang T; Pipia G; Kubiatowski T; Karim P; Ross AH; Zurier R; Litofsky NS; Burstein S
Biochem Pharmacol; 2001 Sep; 62(6):755-63. PubMed ID: 11551521
[TBL] [Abstract][Full Text] [Related]
29. Delta9-Tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo.
Preet A; Ganju RK; Groopman JE
Oncogene; 2008 Jan; 27(3):339-46. PubMed ID: 17621270
[TBL] [Abstract][Full Text] [Related]
30. Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice.
Lichtman AH; Sheikh SM; Loh HH; Martin BR
J Pharmacol Exp Ther; 2001 Sep; 298(3):1007-14. PubMed ID: 11504797
[TBL] [Abstract][Full Text] [Related]
31. Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases.
Ali SA; McHayleh WM; Ahmad A; Sehgal R; Braffet M; Rahman M; Bejjani G; Friedland DM
J Neurosurg; 2008 Aug; 109(2):268-72. PubMed ID: 18671639
[TBL] [Abstract][Full Text] [Related]
32. Effects of chronic exposure to delta9-tetrahydrocannabinol on cannabinoid receptor binding and mRNA levels in several rat brain regions.
Romero J; Garcia-Palomero E; Castro JG; Garcia-Gil L; Ramos JA; Fernandez-Ruiz JJ
Brain Res Mol Brain Res; 1997 Jun; 46(1-2):100-8. PubMed ID: 9191083
[TBL] [Abstract][Full Text] [Related]
33. Opposing actions of chronic Delta9-tetrahydrocannabinol and cannabinoid antagonists on hippocampal long-term potentiation.
Hoffman AF; Oz M; Yang R; Lichtman AH; Lupica CR
Learn Mem; 2007; 14(1-2):63-74. PubMed ID: 17202425
[TBL] [Abstract][Full Text] [Related]
34. Local administration of delta9-tetrahydrocannabinol attenuates capsaicin-induced thermal nociception in rhesus monkeys: a peripheral cannabinoid action.
Ko MC; Woods JH
Psychopharmacology (Berl); 1999 Apr; 143(3):322-6. PubMed ID: 10353438
[TBL] [Abstract][Full Text] [Related]
35. Reversal of cannabinoids (delta9-THC) by the benzoflavone moiety from methanol extract of Passiflora incarnata Linneaus in mice: a possible therapy for cannabinoid addiction.
Dhawan K; Kumar S; Sharma A
J Pharm Pharmacol; 2002 Jun; 54(6):875-81. PubMed ID: 12079005
[TBL] [Abstract][Full Text] [Related]
36. A vapourized Δ(9)-tetrahydrocannabinol (Δ(9)-THC) delivery system part II: comparison of behavioural effects of pulmonary versus parenteral cannabinoid exposure in rodents.
Manwell LA; Ford B; Matthews BA; Heipel H; Mallet PE
J Pharmacol Toxicol Methods; 2014; 70(1):112-9. PubMed ID: 24956154
[TBL] [Abstract][Full Text] [Related]
37. A phase I trial of carboplatin administered by convection-enhanced delivery to patients with recurrent/progressive glioblastoma multiforme.
White E; Bienemann A; Taylor H; Hopkins K; Cameron A; Gill S
Contemp Clin Trials; 2012 Mar; 33(2):320-31. PubMed ID: 22101221
[TBL] [Abstract][Full Text] [Related]
38. Phase II study of accelerated fractionation radiation therapy with carboplatin followed by vincristine chemotherapy for the treatment of glioblastoma multiforme.
Levin VA; Maor MH; Thall PF; Yung WK; Bruner J; Sawaya R; Kyritsis AP; Leeds N; Woo S; Rodriguez L
Int J Radiat Oncol Biol Phys; 1995 Sep; 33(2):357-64. PubMed ID: 7673023
[TBL] [Abstract][Full Text] [Related]
39. Rimonabant-induced Delta9-tetrahydrocannabinol withdrawal in rhesus monkeys: discriminative stimulus effects and other withdrawal signs.
Stewart JL; McMahon LR
J Pharmacol Exp Ther; 2010 Jul; 334(1):347-56. PubMed ID: 20375197
[TBL] [Abstract][Full Text] [Related]
40. Anxiety does not affect the antinociceptive effect of Delta 9-THC in mice: participation of cannabinoid and opioid receptors.
Takahashi RN; Ramos GA; Assini FL
Pharmacol Biochem Behav; 2003 Jul; 75(4):763-8. PubMed ID: 12957217
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
